

David E. Kemp, M.D.
- Curriculum Vitae -
(Revised 08/2009)

OFFICE ADDRESS:

Mood Disorders Program
10524 Euclid Avenue, 12th Floor
Cleveland, Ohio 44106

Telephone: 216/844-2865
FAX 216/844-2875
E-mail: kemp.david@gmail.com

DATE & PLACE OF BIRTH:

December 28, 1977
Youngstown, Ohio

EDUCATION:

06/1996 – 08/1998

B.S. Kent State University
(major in integrated life sciences, summa cum laude)

09/1998 – 05/2002

M.D. Northeastern Ohio Universities College of Medicine
(degree awarded with honors in psychiatry)

06/2002 – 12/2002

Resident in Internal Medicine/Neurology
Northwestern University
Chicago, Illinois

01/2003 – 05/2005

Resident in Psychiatry
Northwestern University
Chicago, Illinois

06/2005 – 06/2006

Chief Resident
Department of Psychiatry
Northwestern University
Chicago, IL

07/2006 – 06/2008

Research Fellowship
Bipolar Disorders Across the Life Cycle Center for Intervention
and Services Research
Co-Directors, Joseph R. Calabrese, M.D. and Robert L. Findling, M.D.
Case Western Reserve University, Cleveland, OH

07/2007 – Present

Clinical Research Scholar's Program (Master's program in Clinical Investigation)
Case Western Reserve University
Cleveland, OH

PROFESSIONAL LICENSES:

06/2006 – 10/2010

State Medical Board of Ohio, License 35.088017

07/2004 – 07/2008

Illinois Department of Professional Regulation, License 036-111724

BOARD CERTIFICATION:

2007 Diplomat, American Board of Psychiatry and Neurology

PROFESSIONAL EXPERIENCE:

12/2008 – Present Assistant Professor of Psychiatry
Case Western Reserve University School of Medicine
Tenure Track

08/2008 – Present Director, Mood & Metabolic Clinic
Mood Disorders Program
Case Western Reserve University School of Medicine
Cleveland, Ohio

07/2007 – 12/2008 Instructor of Psychiatry
Case Western Reserve University School of Medicine
Cleveland, Ohio

06/2004 – 06/2006 Deputy Representative to the Area IV Council, Illinois Psychiatric Society

06/2005 – 06/2006 Staff Physician, Evanston Northwestern Healthcare

MEMBERSHIP:

2000 – Present American Psychiatric Association
2006 – Present International Society for Bipolar Disorders
2007 – Present American Diabetes Association
2008 – Present Obesity Society

HONORS & AWARDS:

07/2009 American College of Neuropsychopharmacology Young Investigator Award

06/2007 New Clinical Drug Evaluation Unit (NCDEU) New Investigator Award

05/2007 American Psychiatric Association Research Colloquium for Young Investigators

03/2007 Career Development Institute for Bipolar Disorder Award,
“A workshop on launching and maintaining a career in mental health research in bipolar disorder”

01/2007 John C. and Sally S. Morley Family Foundation Award,
“Achieving Remission and Recovery in Depression: The Influence of Metabolic Syndrome on Treatment Outcomes”

06/2006 Northwestern University Scholar’s Day Award, “Best PGY-IV Manuscript”

06/2006 Henry P. Laughlin Fellow of The American College of Psychiatrists

05/2006 American Psychiatric Association Research Colloquium for Young Investigators

04/2006 Workshop on Clinical Trials in Psychopharmacology Travel Fellowship,
American Society of Clinical Psychopharmacology

08/2005 Emory University Psychiatry Residents' Symposium Travel Award

06/2005 Virginia Tarlow, M.D. Award in Psychiatry for Outstanding Performance on the
National Psychiatry Residency In-Training Examination (PRITE)

05/2002 Excellence in Psychiatry Award, Northeastern Ohio Universities College of
Medicine

EDITORIAL BOARDS:

2009 – Present BMC Psychiatry, Associate Editor

REFEREE FOR JOURNALS:

American Journal of Psychiatry
Archives of General Psychiatry
Bipolar Disorders
British Journal of Psychiatry
CNS Spectrums
European Psychiatry
Expert Opinion on Drug Metabolism & Toxicology
Human Psychopharmacology: Clinical and Experimental
Journal of Affective Disorders
Journal of Clinical Psychopharmacology
Journal of Immigrant and Minority Health
Journal of Medical Economics
Journal of Psychopharmacology
Lancet
Medscape General Medicine
Pharmacology, Biochemistry, and Behavior
Pharmacopsychiatry
Primary Care Companion to the Journal of Clinical Psychiatry
Progress in Neuro-Psychopharmacology & Biological Psychiatry
Psychiatric Times
Psychosomatic Medicine

SERVICE:

I. Case Western Reserve University School of Medicine, Medical Student Curriculum

06/2008 – Present Representative to Block 6 Curriculum Committee: Cognition, Sensation, and Movement

COMMITMENT TO TEACHING:

MEDICAL STUDENT TEACHING

I. Third Year Psychiatry Research Rotation

<u>Medical Student Mentored</u>	<u>Years Taught</u>	<u>Contact/Year</u>
Kathryn Feldman	2007	3 months/year (Case)
Ellyn Johnson	2009	4 months/year (Case)

II. Third Year Psychiatry Rotation (Core Clerkships)

LECTURES

<u>Topic</u>	<u>Years Taught</u>	<u>Contact/Year</u>
1) Psychopharmacology	2005-2006	52 hours/14 students (Northwestern)

The following lectures were presented every 4 weeks to a group of third-year medical students:

- 1) Psychopharmacological Treatment of Major Depressive Disorder
- 2) Bipolar Disorder: Phenomenology, Pathophysiology, and Treatment
- 3) Approach to the Treatment of Patients with Psychotic Disorders
- 4) Emerging Treatments for Anxiety Disorders

2) Introduction to Psychopharmacology	2008-Present	1.5 hours per month/5 students (Case) 10 total contact hours for 35 students
---------------------------------------	--------------	---------------------------------------------------------------------------------

SUPERVISION

<u>Topic</u>	<u>Years Taught</u>	<u>Contact/Year</u>
Clinical Case Conference Supervised residents and medical students after taking overnight hospital call in the psychiatric emergency department.	2005-2006	26 hours/3 students (Northwestern)

III. Second Year Psychiatry Rotation (MIND Committee, Block 6)

LECTURES

<u>Topic</u>	<u>Years Taught</u>	<u>Contact/Year</u>
1) Clinical Interviewing in Psychiatry	2006	6 hr/6 students (Case Western)

Instructed second year medical students on the art of clinical interviewing using live patients. Two, three-hour seminars were conducted.

2) Alcoholism and Substance Use Disorders	<u>Years Taught</u> 2006	<u>Contact/Year</u> 2 hr/16 students (Northwestern)
-------------------------------------------	-----------------------------	--------------------------------------------------------

3) Psychopharmacology of Mood Disorders	<u>Years Taught</u> 2009	<u>Contact/Year</u> 1 hr/60 students (Case Western)
-----------------------------------------	-----------------------------	--------------------------------------------------------

MEDIUM SIZE GROUPS

<u>Topic</u>	<u>Years Taught</u>	<u>Contact/Year</u>
Mood Disorders	2006	1 hr/13 students
Mood Disorders and Anxiety	2009	2 hr/16 students
Psychopharmacology Case Studies	2009	2 hr/32 students
Pursuing a Research Career in Psychiatry: A Junior Faculty Perspective	2009	1 hr/21 students

IV. Block 6 – CWRU School of Medicine Inquiry Group

<u>Topic</u>	<u>Year</u>
Inquiry Group – Mood Disorders	2007

Developed a 16-page instructional case vignette for use in a 2-hour seminar on the diagnosis and management of mood disorders. Upon completion, students will learn to distinguish presentations of unipolar depression from bipolar depression, construct a differential diagnosis for mood disorders, and present an initial treatment plan.

RESIDENT TEACHING

I. Core Didactics

<u>Lecture</u>	<u>PGY</u>	<u>Year</u>	<u>Contact hours</u>
Metabolic Abnormalities in Mood Disorders	2	2009	1.0
Introduction to Statistics	2	2009	1.0
What Effectiveness Trials Can Teach Us	4	2008	1.0
Metabolic Abnormalities in Mood Disorders	2	2008	1.0
Pathophysiology of Mood Disorders	2	2008	1.0
Depressive Disorders Part I	1	2008	1.0
Depressive Disorders Part II	1	2008	1.0
Introduction to Psychiatric Research	1	2008	1.0
Project Design and Consulting with a Statistician	2	2008	1.5
STAR*D, STEP-BD, and LiTMUS	4	2007	1.5
Pathophysiology of Bipolar Disorder	2	2007	1.5
Metabolic Abnormalities in Mood Disorders	2	2007	1.5
Project Design and Consulting with a Statistician	2	2007	1.5
Introduction to Psychiatric Research	1	2007	1.5
Pharmacological Treatment of Acute Mania	1&2 (Emerg. Med.)	2006	1.5

II. Mock Boards

<u>Candidate</u>	<u>PGY</u>	<u>Year</u>	<u>Contact hours</u>
Marianne Jhee, MD	2	2007	2

III. Journal Club

<u>Date</u>	<u>Topic</u>	<u>Role</u>
06/2008	Aripiprazole for the adjunctive treatment of major depression	Faculty Discussant
07/2008	Bi-directional association between depression and diabetes	Faculty Discussant
08/2008	Pregabalin in generalized anxiety disorder	Faculty Discussant
09/2008	Lamotrigine as add-on therapy in schizophrenia	Faculty Discussant
11/2008	Eszopiclone for insomnia and major depression	Faculty Discussant

02/2009	Cardiac death associated with atypical antipsychotic drugs	Faculty Discussant
03/2009	Dissociative disorders and suicidality	Faculty Discussant
06/2009	Psilocybin and mystical experiences	Faculty Discussant
08/2009	Risk-taking behaviors among adolescents exposed to trauma	Faculty Discussant

IV. Resident Supervision (Weekly)

06/2008 – 06/2009 Tiffany Thomas, MD

RESEARCH AS PRINCIPAL INVESTIGATOR:

NIMH/FEDERAL FUNDING

<u>Grant Number</u>	<u>Grant Title</u>	<u>Role in Project and Current % Effort</u>	<u>Years</u>	<u>Source \$ Amount</u>
5K12RR023264-03 (Richard Rudick, MD)	Multidisciplinary Clinical Research Training Program Award (K-12) <i>(Joseph R. Calabrese, MD and Faramarz Ismail-Beigi, MD, PhD, Primary Mentors)</i>	Principal Investigator 75% current effort	06/07-06/10	NIH \$240,000

The Multidisciplinary Clinical Research Training Program is supported through the “NIH Roadmap” and intended to train junior investigators in the knowledge and skill of conducting multidisciplinary research. The pilot project linked to this award is predicated on the overlapping pathophysiology between mood disorders and metabolic syndrome. The project will test whether an insulin sensitizer (peroxisome proliferator-activated receptor gamma agonist) can reduce depression symptoms. If effective, this research will represent a paradigm shift in the way depression is conceptualized and treated by focusing on insulin sensitivity and immunoinflammatory activation as targets to reduce depression severity.

FOUNDATION AWARDS

<u>Grant Number</u>	<u>Grant Title</u>	<u>Role in Project and Current % Effort</u>	<u>Years</u>	<u>Source \$ Amount</u>
N/A	Pioglitazone for Bipolar Depression and Comorbid Metabolic Syndrome or Insulin Resistance	Principal Investigator 10% current effort	10/08-10/10	Cleveland Foundation \$150,000

The Grossman Family Trust, in coordination with the Cleveland Foundation, has awarded a 2-year grant to investigate the increased risk for metabolic syndrome in patients with bipolar disorder. This clinical trial will test whether pioglitazone, an insulin sensitizer, can effectively reduce the symptoms of bipolar depression while simultaneously decreasing the insulin resistance associated with metabolic syndrome.

N/A	Research Development Award <i>(Joseph R. Calabrese, MD, Primary Mentor)</i>	Principal Investigator 5% current effort	07/07-06/09	ISBD \$20,000
-----	---------------------------------------------------------------------------------------	----------------------------------------------------	-------------	------------------

The International Society for Bipolar Disorders (ISBD) recognizes the vital role of developing the next generation of leaders in the field of bipolar disorder and offers one \$20,000 fellowship award annually to support research in the field of bipolar disorders. The main purpose of this award is to provide an opportunity for a trainee to get training in research methodology that he/she may not have access to otherwise.

N/A	Glucose-Lowering Drugs in the Treatment of Bipolar Depression	Principal Investigator 5% current effort	07/08-07/10	NARSAD \$60,000
-----	----------------------------------------------------------------------	----------------------------------------------------	-------------	--------------------

N/A	Influence of Metabolic Syndrome on Treatment Outcomes	Principal Investigator	07/07-06/09	Morley Foundation \$10,000
-----	--------------------------------------------------------------	-------------------------------	-------------	-------------------------------

INDUSTRY

NCT00771134	Efficacy and Safety of LuAA39959 in Bipolar Depression	Principal Investigator	01/09-12/09	Lundbeck \$77,262
-------------	---------------------------------------------------------------	-------------------------------	-------------	----------------------

This study is a phase II placebo-controlled and quetiapine-referenced clinical trial using a fixed dose of Lu AA39959 in the treatment of patients with bipolar I or II disorder. Lu AA39959 modulates potassium channel activity and may represent a novel mechanism of action for treating bipolar disorder.

RESEARCH AS CO-INVESTIGATOR:

NIMH/FEDERAL FUNDING

N01MH80001	Lithium Use in Bipolar Disorder Study (<i>Andrew Nierenberg, MD, Coordinating PI</i>)	Co-Investigator 10% current effort	03/08-02/11	NIMH \$598,054
MH-62650	Combination Therapy in Rapid Cycling Bipolar Disorder (<i>Joseph R. Calabrese, MD, Principal Investigator</i>)	Co-Investigator	2/02-6/07	NIMH \$573,750
(N01MH90003)	Combination of Duloxetine and Bupropion SR in Patients with Depression (<i>A. John Rush, MD, Principal Investigator; William S. Gilmer, MD, Site Principal Investigator</i>)	Co-Investigator	03/06-07/06	Bridge Grant from STAR*D
N01MH90003	Sequenced Treatment Alternatives to Relieve Depression (STAR*D) (<i>A. John Rush, MD, Principal Investigator; William S. Gilmer, MD Site Principal Investigator</i>)	Study Clinician	04/01-12/05	NIMH \$637,616

FOUNDATION AWARDS

Source

<u>Grant Number</u>	<u>Grant Title</u>	<u>Role in Project</u>	<u>Years</u>	<u>\$ Amount</u>
02T-183	Combination Therapy in Dual Diagnosis Rapid Cycling Bipolar Disorder <i>(Joseph R. Calabrese, MD, Principal Investigator)</i>	Co-Investigator	09/02-06/07	Stanley Foundation \$805,230

INDUSTRY

<u>Grant Number</u>	<u>Grant Title</u>	<u>Role in Project</u>	<u>Years</u>	<u>Source</u> <u>\$ Amount</u>
N/A	Armodafinil for the Treatment of Major Depressive Episodes in Bipolar I Disorder	Co-Investigator	10/07-09/08	Cephalon \$177,575
N/A	Double-Blind, Placebo-Controlled Divalproex Sodium-ER in Bipolar Depression <i>(David J. Muzina, MD, Principal Investigator)</i>	Co-Investigator	07/03-10/07	Abbott \$227,500
N/A	Biomarkers for Rapid Identification of Treatment Effectiveness in Major Depression <i>(Andrew Leuchter, MD, Principal Investigator; William S. Gilmer, MD, Site Principal Investigator)</i>	Co-Investigator	3/06-07/06	Aspect Medical \$218,000
N/A	Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder <i>(S. Nassir Ghaemi, MD, Principal Investigator)</i>	Co-Investigator	07/04-06/06	Janssen \$30,230
N/A	Depakote-ER for Depressive and Anxiety Symptoms in Non-Refractory Bipolar Depression <i>(S. Nassir Ghaemi, MD, Principal Investigator)</i>	Co-Investigator	06/04-06/06	Abbott \$60,000
44-01102-000	Repetitive Transcranial Magnetic Stimulation in Patients with Major Depression Previously Non-Responsive to Active or Sham rTMS Treatment <i>(William S. Gilmer, MD, Site Principal Investigator)</i>	Co-Investigator	08/04-07/05	Neuronetics \$45,395
44-01101-000	Repetitive Transcranial Magnetic Stimulation in Patients with Major Depression <i>(William S. Gilmer, MD, Site Principal Investigator)</i>	Co-Investigator	08/04-07/05	Neuronetics \$169,300
44-01103-000	Maintenance Repetitive Transcranial Magnetic Stimulation	Co-Investigator	07/04-07/05	Neuronetics \$37,520

in Patients with Major Depression
(William S. Gilmer, MD, Site Principal
Investigator)

PUBLICATIONS:

Peer-Reviewed Manuscripts

1. **Kemp DE** and Franco KN. Possible leukopenia associated with long-term use of echinacea. Journal of the American Board of Family Practice. 2002;15:417-419.
2. **Kemp DE**, Malhotra S, Franco KN, Tesar G, Bronson DL. Heart disease and depression: Don't ignore the relationship. Cleveland Clinic Journal of Medicine. 2003;70:745-754.
3. Calabrese JR, Muzina DJ, **Kemp DE**, Sachs GS, Thompson TR, Klingman D, Reed ML, Hirschfeld RM. Predictors of bipolar disorder risk among patients currently treated for major depression. Medscape General Medicine. 2006;8(3) [online journal].
4. Muzina DJ, **Kemp DE**, Gao K, Gajwani P, Calabrese JR. Atypical antipsychotics in bipolar depression: Applying emerging evidence to clinical practice. Psychiatric Annals. 2006;36:646-652.
5. Muzina DJ, Gajwani P, **Kemp DE**, Gao K, Calabrese JR. Antiepileptic drugs for acute bipolar depression: Applying data to clinical practice. Psychiatric Annals. 2006;36:637-644.
6. Gajwani P, **Kemp DE**, Muzina DJ, Xia G, Gao K, Calabrese JR. Acute treatment of mania: An update on new medications. Current Psychiatry Reports. 2006;8:504-509.
7. **Kemp DE**, Gilmer WS, Fleck J, Dago PL. An association of intrusive, repetitive phrases with lamotrigine treatment in bipolar II disorder. CNS Spectrums. 2007;12(2):106-111.
8. **Kemp DE**, Gilmer WS, Fleck J, Straus JL, Dago PL, Karaffa M. Aripiprazole augmentation in treatment-resistant bipolar depression: Early response and development of akathisia. Progress in Neuropsychopharmacology and Biological Psychiatry. 2007;31(2):574-7.
9. **Kemp DE**, Dago PL, Straus JL, Fleck J, Karaffa M, Gilmer WS. Aripiprazole Augmentation for Treatment-Resistant Bipolar Depression: Sustained Remission after 36-Months. Journal of Clinical Psychopharmacology. 2007;27(3):304-5.
10. Muzina DJ, **Kemp DE**, and McIntyre RS. Differentiating major depressive disorders from bipolar disorders: Treatment implications. Annals of Clinical Psychiatry. 2007;19(4):305-12.
11. Ghaemi SN, Gilmer WS, Goldberg JF, Zablotsky B, **Kemp DE**, Kelley ME, Bauer AD, Fleck J, Filkowski MM, Stan VA, Dunn RT. Divalproex in the treatment of acute bipolar depression: A preliminary, double-blind, randomized, placebo-controlled pilot study. Journal of Clinical Psychiatry. 2007;68(12):1840-4.
12. Xia G, Gajwani P, Muzina DJ, **Kemp DE**, Gao K, Ganocy SJ, Calabrese JR. Treatment-emergent mania in unipolar and bipolar depression: Focus on repetitive transcranial magnetic stimulation. International Journal of Neuropsychopharmacology. 2008;11(1):119-30.

13. Gao K, Ganocy SJ, Gajwani P, Muzina DJ, **Kemp DE**, Calabrese JR. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. Journal of Clinical Psychiatry. 2008;69:203-209.
14. McIntyre RS, Muzina DJ, **Kemp DE**, Blank D, Woldeyohannes HO, Lofchy J, Soczynska JK, Banik S, Konarski JZ. Bipolar disorder and suicide: Synthesis and clinical translation. Current Psychiatry Reports. 2008;10(1):66-72.
15. Gao K, **Kemp DE**, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. Journal of Clinical Psychopharmacology. 2008;28(2):203-209.
16. **Kemp DE**, Hirschfeld RMA, Ganocy SJ, Elhaj O, Slembariski R, Bilali S, Conroy C, Pontau J, Findling RL, Calabrese JR. Screening for bipolar disorder in a county jail at the time of criminal arrest. Journal of Psychiatric Research. 2008;42(9):778-86.
17. **Kemp DE**, Muzina DJ, McIntyre RS, Calabrese JR. Bipolar Depression: Trial-Based Insights to Guide Patient Care. Dialogues in Clinical Neuroscience. 2008;10:181-192.
18. Gao K, Tolliver B, **Kemp DE**, Verduin ML, Ganocy SJ, Bilali S, Brady K, Shim SS, Findling RL, and Calabrese JR. Differential interactions between comorbid anxiety and substance use disorder in rapid-cycling bipolar I or II disorder. Journal of Affective Disorders. 2008;110:167-73.
19. Gao K, Verduin ML, **Kemp DE**, Tolliver B, Ganocy SJ, Elhaj O, Bilali S, Brady K, Findling RL, and Calabrese JR. Clinical Correlates of patients with rapid-cycling bipolar disorder and a recent history of substance use disorder: A subtype comparison. Journal of Clinical Psychiatry. 2008 Jul;69(7):1057-63.
20. Calabrese JR, **Kemp DE**. Bipolar drug development: are we getting closer to the real world? Am J Psychiatry. 2008;165(10):1234-6.
21. **Kemp DE**, Calabrese JR, Ismail-Beigi F. Depression and diabetes. JAMA. 2008;300(18):2115-6.
22. Gao K, **Kemp DE**, Ganocy SJ, Muzina DJ, Xia G, Findling RL, Calabrese JR. Treatment-emergent mania/hypomania during antidepressant monotherapy in patients with rapid cycling bipolar disorder. Bipolar Disord. 2008;10(8):907-15.
23. **Kemp DE**, Gao K, Ganocy S, Rapport D, Elhaj O, Bilali S, Conroy C, Findling R, and Calabrese JR. A 6-Month, Double-Blind, Maintenance Trial of Lithium Monotherapy Versus the Combination of Lithium and Divalproex for Rapid-Cycling Bipolar Disorder and Co-Occurring Substance Abuse or Dependence. Journal of Clinical Psychiatry. 2009;70(1):113-21.
24. McIntyre RS, Rasgon NL, **Kemp DE**. Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. Curr Diab Rep. 2009;9(1):51-9.
25. Ghaemi SN, Gilmer WS, Dunn RT, Hanlon RE, **Kemp DE**, Bauer AD, Chriki L, Filkowski MM, Harvey PD. A double-blind, placebo-controlled pilot study of galantamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder. Journal of Clinical Psychopharmacology. 2009;29(3):291-5.
26. **Kemp DE**, Ismail-Beigi F, Calabrese JR. Antidepressant response associated with pioglitazone: Support for an overlapping pathophysiology between major depression and metabolic syndrome. Am J Psychiatry. 2009;166(5):619.

27. **Kemp DE**, Gao K, Ganocy SJ, Caldes E, Feldman K, Chan PK, Conroy C, Bilali S, Findling RL, Calabrese JR. Medical and Substance Use Comorbidity in Bipolar Disorder. Journal of Affective Disorders. 2009 Jul;116(1-2):64-9.
28. Gao K, Tolliver BK, **Kemp DE**, Ganocy SJ, Bilali S, Brady KL, Findling RL, Calabrese JR. Correlates of historical suicide attempt in rapid-cycling bipolar disorder: a cross-sectional assessment. J Clin Psychiatry. 2009;70(7):1032-40.

In-Press Peer-Reviewed Manuscripts

29. Goldstein BI, **Kemp DE**, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. Journal of Clinical Psychiatry. In press.
30. **Kemp DE**, Calabrese JR, Tran Q, Pikalov A, Eudicone JM, Baker RA. Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder. Journal of Clinical Psychiatry. In press.

Books, Book Chapters, Invited Articles

31. **Kemp DE**, Gao K, Muzina DJ, Calabrese JR. Progress in the treatment of bipolar depression: Advances and challenges. Psychiatric Times. 2006; August, Volume XXIII, No. 9.
32. Gilmer WS and **Kemp DE**. STAR*D: What have we learned thus far? International Drug Therapy Newsletter. 2006;41:75-82.
33. Benson RR, Manthana P, **Kemp DE**. Behavioral neurology and psychiatry. In: Borsody MK ed. Comprehensive Board Review in Neurology. Thieme, New York, New York, 2007, pp 154-182.
34. **Kemp DE**, Gao K, Muzina DJ, Gajwani P, Calabrese JR. Trial-based advances in the treatment of bipolar depression. Progress in Neurotherapeutics and Neuropsychopharmacology. 2007;2(1):193-212.
35. **Kemp DE**, Muzina DJ, Gao K, Calabrese JR. Pharmacological treatments for bipolar depression: Focus on atypical antipsychotics. Directions in Psychiatry. 2007;27(2):99-112.
36. Muzina DJ, **Kemp DE**, Calabrese JR. Mood Stabilizers. Chapter 103, In: Tasman A, Kay J, Lieberman JA, First MB, Maj M, ed. Psychiatry, Third Edition. Volume 2. Wiley-Blackwell. 2008, 2202-2222.
37. Gao K, **Kemp DE**, Calabrese JR. Pharmacological treatment of the maintenance phase of bipolar depression: focus on relapse prevention studies and the impact of design on generalizability. In: Milestones in Drug Therapy series (M Parnham, J Bruinvels, series eds), Bipolar Depression: Molecular Neurobiology, Clinical Diagnosis, and Pharmacotherapy. (CA Zarate Jr, HK Manji, eds). Birkhauser Verlag AG, Switzerland, Springer Science + Business Media 2009, page 159 – 179.
38. Muzina DJ, **Kemp DE**, Yatham LN, Calabrese JR. Bipolar Depression: Diagnosis and Treatment. In: Yatham LN ed. Bipolar Disorder: A clinician's guide to biological treatments. Taylor & Francis. 2009, 19-44.
39. **Kemp DE**, Muzina DJ, Gao K, Calabrese JR. Antiepileptic Drugs in the Treatment of Rapid Cycling Bipolar

Disorder and Bipolar Depression. In: McElroy SL ed. Antiepileptic Drugs to Treat Psychiatric Disorders. Informa Healthcare. 2008, 155-176.

40. **Kemp DE**, Muzina DJ, Gao K, Calabrese JR: Lamotrigine. In: Textbook of Psychopharmacology (A.F. Schatzberg, CB Nemeroff, Eds. In Press.
41. Gajwani P, Muzina DJ, **Kemp DE**, Gao K, Calabrese JR. Update on Quetiapine in the Treatment of Bipolar Disorder: Results from the BOLDER studies. Neuropsychiatric Disease and Treatment. In press.
42. **Kemp D**, Canan F, Goldstein BI, McIntyre R. Long-acting Risperidone: A Review of Its Role in the Treatment of Bipolar Disorder. Advances in Therapy. 2009;26(6):588-99.

FIRST-AUTHORED PEER-REVIEWED POSTER PRESENTATIONS

1. Divalproex Extended-Release as Monotherapy in the Treatment of Acute Bipolar Depression, American Psychiatric Association Junior Investigators' Colloquium, Toronto, Canada, May 2006
2. Predictors of Bipolar Disorder Risk Among Patients Currently Treated for Major Depression [poster], New Clinical Drug Evaluation Unit, Boca Raton, Florida, June 2006
3. Lithium Monotherapy Versus the Combination of Lithium and Divalproex for Rapid Cycling Bipolar Disorder Comorbid with Substance Abuse or Dependence: A 6-Month, Double-Blind, Maintenance Trial [poster], American College of Neuropsychopharmacology, Hollywood, Florida, December 2006
4. Metabolic Syndrome in Patients Enrolled in a Clinical Trial of Aripiprazole in the Maintenance Treatment of Bipolar I Disorder [poster], American Psychiatric Association Annual Meeting, San Diego, California, May 2007
5. Subcomponents of Metabolic Syndrome in Patients Enrolled in a Clinical Trial of Aripiprazole for the Maintenance Treatment of Bipolar Disorder [poster], American College of Neuropsychopharmacology, Boca Raton, Florida, December 2007
6. Predictive Value of Early Improvement in Aripiprazole, 8-Week, Bipolar Depression Trials (Studies CN 138-096 and CN 138-146) [poster], New Clinical Drug Evaluation Unit, Phoenix, Arizona, May 2008
7. Medical Comorbidity in 225 patients with bipolar disorder: greater depression severity is associated with illnesses of the endocrine/metabolic system [poster], American College of Neuropsychopharmacology, Scottsdale Arizona, December 2008
8. Predictive Effect of Metabolic Syndrome on Aripiprazole Treatment Response in Patients with Bipolar Disorder (CN138-010) [poster], American Psychiatric Association Annual Meeting, San Francisco, California, May 2009

INVITED PRESENTATIONS:

1. “The Metabolic Syndrome: Implications for Clinical Trials in Bipolar Disorder”. Presented to Schizophrenia and Bipolar Disorder Knowledge Summit. Wyeth Pharmaceuticals, Collegeville, PA. October 6, 2007.
2. “The Metabolic Syndrome: Applying our Knowledge to Clinical Research in Mood Disorders”. Presented to Bipolar Disorder Interventions and Services Research Center P20 Lecture Series. Case Western Reserve University, Cleveland, OH. November 27, 2007.
3. “Are Antidiabetic Drugs the Next Treatment for Depression?”. Presented to Case Western Reserve University Grand Rounds, Cleveland, OH. February 22, 2008.
4. “Long-Term Treatment Strategies Tailored to Comorbid Presentations of Bipolar Disorder”. Presented to American Psychiatric Association Satellite Symposium entitled Individualizing Treatment Plans for Total Health in Patients with Bipolar Disorder, Washington, DC. May 6, 2008.
5. “Balancing Generalizability and Assay Sensitivity in Bipolar Disorder Treatment Trials: Focus on Excluding Patients with Comorbid Axis III Conditions”. Presented to New Clinical Drug Evaluation Unit (NCDEU) New Investigator Awardee Panel, Phoenix, AZ. May 29, 2008.
6. “Bipolar Depression: New Research Findings and the Relationship to Comorbid Metabolic Syndrome”. Presented to Northcoast Behavioral Healthcare Grand Rounds, Northfield, OH. June 13, 2008.
7. “Treating the Mind and Body for Total Health.” Healthy Minds Across America, sponsored by NARSAD. Cleveland, OH. September 14, 2008.
8. “The Mind-Body Connection: Can Treating Insulin Resistance Improve Mood?” Presented to MetroHealth Center for Health Care Research & Policy. Cleveland, OH. December 12, 2008.
9. “Mood Disorders: New Research Findings.” Presented to Geauga County National Alliance for the Mentally Ill (NAMI). Chardon, OH. January 15, 2009.
10. “Metabolic Syndrome Across the Life Cycle in Mood Disorders”. Presented to Lutheran Hospital CME Program entitled Mood Disorders: New Perspectives in Pathophysiology and Treatment. Cleveland, OH. February 20, 2009.
11. “Mood Disorders and Metabolic Syndrome: Pathophysiologic Overlap and Treatment Opportunities”. Presented to All-Ohio Institute on Community Psychiatry. Beachwood, OH. March 21, 2009.
12. “Metabolic Syndrome Across the Life Cycle in Bipolar Disorder”. Presented to American Psychiatric Association Satellite Symposium entitled Bipolar Disorder Throughout the Life Cycle: Treatments and Treatment Experience, San Francisco, California. May 19, 2009.

MEDIA INTERVIEWS:

1. WKYC Channel 3, Cleveland, Ohio. Noon News Health Segment, Interviewed by Maureen Kyle. October 24, 2008.